Toll free

18002022232

Co-founder, SUNACT
Specialist in Solid Tumors & Advanced Cancer Therapies

Dr. (Prof.) Vijay Patil

Transforming cancer care through innovation, accessibility, and compassion.
About Dr. Patil

Dr. (Prof.) Vijay Patil, MD, DM, is an oncologist specializing in solid tumors and advanced cancer therapies. With 19 years of experience, he has been dedicated to clinical practice, cellular therapies, and innovative drug development. He has authored more than 750 peer-reviewed publications in leading international journals, including the Journal of Clinical Oncology, The Lancet Global Health, Oral Oncology, Cancer, Cancer Cell, and ASCO publications.

He completed his MBBS from Grant Medical College & KEM Hospital, Mumbai, in 2006, completed his MD in Radiotherapy at PGIMER, Chandigarh, in 2009 with the Kataria Gold Medal, and earned his DM in Medical Oncology from Tata Memorial Centre, Mumbai, in 2013 with a Gold Medal.

Through his clinical expertise and research leadership at SunAct, Dr. (Prof.) Patil continues to contribute to advancements in oncology and strives to improve outcomes for patients worldwide.

He completed his MBBS from Grant Medical College & KEM Hospital, Mumbai, in 2006, completed his MD in Radiotherapy at PGIMER, Chandigarh, in 2009 with the Kataria Gold Medal, and earned his DM in Medical Oncology from Tata Memorial Centre, Mumbai, in 2013 with a Gold Medal.

Overview

Over the course of his career, Dr. (Prof.) Vijay Patil has cared for more than 12 lakhs patients and contributed to the development of new treatment approaches and clinical criteria in oncology. He has also played an active role in national and international clinical trials, helping to bring emerging therapies into practice.
His treatment experience spans:

  • Chemotherapy – 5,00,000+ patients
  • Metronomic Chemotherapy – 1,50,000+ patients
  • Targeted Therapies – 1,00,000+ patients
  • Immunotherapy – 10,000+ patients
  • CAR T-Cell Therapy – among the early adopters in India, involved in patient selection, administration, and follow-up care.

Through a combination of clinical experience and ongoing research, he continues to contribute to advancements in cancer treatment for patients across the country.

Head and Neck Cancer

  • Low-dose immunotherapy: Developed a low-dose immunotherapy regimen that is an alternative standard of care, bringing treatment costs down by more than 90%.
  • Double metronomic chemotherapy: Conceptualized an oral, low-cost regimen that was proven to be more effective and have fewer side effects than the previous intravenous standard treatment. This regimen has since entered practice guidelines.
  • Triple metronomic chemotherapy: Developed an alternative regimen to immunotherapy for a subset of platinum-refractory head and neck cancer patients, which proved similarly effective at under 1% of the cost. The results were published in the Journal of clinical oncology.
  • 3 weekly cisplatin: A phase 3, randomized study provided the first robust data on the optimal schedule for cisplatin usage with radiation.
  • Nimotuzumab: A randomized phase 3 study on over 500 patients proved the efficacy of adding the novel drug Nimotuzumab to cisplatin.
  • Docetaxel: A large phase 3 study proved that adding Docetaxel as a radiosensitizer to radiation improved outcomes in cisplatin-ineligible patients.
  • Neoadjuvant chemotherapy for organ preservation: A randomized study proved that giving neoadjuvant chemotherapy could shrink jaw tumors, allowing for surgical removal without having to remove the jaw, thus preserving it for the patient.
  • Neoadjuvant chemotherapy for borderline resectable cancers: Developed a strategy where neoadjuvant chemotherapy shrinks advanced tumors enough for them to be operated on, thus prolonging patients' lifespan.
  • Other Head and Neck Cancer Treatments: Has experience treating Thyroid cancer, Salivary gland tumors, Skull base tumors, and NUT midline carcinomas with various systemic therapies. He also developed the neoadjuvant regimen of Cisplatin & etoposide in sinonasal malignancies.


Thoracic Tumours

  • EGFR mutated tumors: A phase 3 study proved that an oral tablet of gefitinib was superior to the prevalent IV first-choice treatment. A subsequent study showed that adding IV chemotherapy to the oral tablet was even better, and this is now an accepted standard treatment guideline.
  • Low-dose gemcitabine: Conceptualized and proved an alternative treatment equally effective to the standard treatment for a type of lung cancer, while being 25% cheaper.
  • Erlotinib maintenance: Proved that an oral drug gave a similar quality of life as the currently used IV drug for maintenance in a lung cancer, providing a cost-effective alternative that reduced hospital visits.
  • Immunotherapy in NSCLC: Helped establish the safety and efficacy of immunotherapy in lung, esophageal, and other cancers in India.
  • Targeted therapies: Has one of the largest published experiences with numerous targeted therapies for various mutations in lung and other cancers.

 

Neuro-Oncology

  • Video follow-ups: A randomized study showed that video follow-ups can effectively substitute for clinical follow-ups for patients with gliomas, which was a great boon during the COVID-19 pandemic.
  • Mebendazole in glioma: A phase 1 study was undertaken to repurpose the anti-parasitic medicine mebendazole for the treatment of glioblastoma.
  • Bevacizumab: Helped establish the role of generic and low-dose bevacizumab through publications.
  • Brain metastasis clinic: A multidisciplinary clinic started in April 2018 improved care by changing the treatment plan for nearly half of the patients with difficult brain metastasis cases.

 

Uro-Oncology

  • Studied and established the role of Paclitaxel-Platinum as adjuvant and palliative therapy in Penile cancers.
  • Established the safety and efficacy of multiple therapies for Renal cell carcinoma and Prostate cancer.

 

Gastrointestinal and Breast/Gynecological Cancers

  • Has established and studied multiple regimens in various settings for GI tumors.
  • Established internationally recognized protocols for treatment in Breast and Gynecological cancers while at Malabar Cancer center.

Dr. (Prof.) Vijay Patil is a preeminent figure in oncology, celebrated for his innovative spirit and patient-centered philosophy. His groundbreaking work has been recognized with numerous national and international honors, solidifying his reputation as a leader in his field. He was awarded the prestigious Gold Medal in Medical Oncology at Tata Memorial Centre, an honor that recognizes not only his academic excellence but also his clinical innovation. Furthermore, he has been honored with the National Young Oncologist Award for his exemplary leadership in clinical research and mentorship. A frequent keynote speaker at major oncology conferences, Dr. Patil is widely respected for his ability to translate complex, cutting-edge science into tangible, real-world treatment solutions that benefit patients.

Honors & Awards

Professor in Medical Oncology (2022-till date, SunAct - Advanced Cancer Therapies) 

  • ASCO Annual Conference, Oral Presentation (2024)
  • Centre of Excellence Award for Cell & Gene Therapy (2024)

 

Professor in Medical Oncology (2020-2022, Tata Memorial Hospital, Mumbai)

  • ASCO annual conference Oral presentation 2020
  • ASCO annual conference Oral presentation 2022
  • ICON Oration 2022-ICON's Geeta Rameshchandra Gandhi Oration
  • SHRI VIJAY BATRA RESEARCH FOUNDATION (ADLEY GROUP) AWARD for the year 2022

 

Associate Professor in Medical Oncology (2017-December 2019, Tata Memorial Hospital, Mumbai)

  • ISNO best paper (poster) 2017
  • ISNO best paper (oral) 2018
  • ASCO annual conference Oral presentation 2018
  • ESMO Asia travel grant 2018
  • FHNO Best paper Award 2019

 

Assistant Professor in Medical Oncology (2015-December 2016, Tata Memorial Hospital, Mumbai)

  • ISMPO best paper- Kala Venkat award 2016
  • ESMO Asia travel grant 2016

 

Assistant Professor in Medical Oncology (2013-2014, Malabar Cancer Centre, Kerala, India)

  • ISO best paper award in ICC 2013
  • ICON best geriatric case award 2014
  • ASCO-IDEA AWARD 2014
  • Best of ASCO India award 2014

 

DM, Medical Oncology (2010-2013, TMH, Mumbai)

  • Gold medal for standing first in Medical oncology for the year 2013
  • Best poster award in ISO conference, Bhubaneswar 2011
  • Best paper (oral presentation) award in ISMPO conference Vizag 2012
  • ACORD Fellowship, Australia 2012

 

MD (2006-2009, PGIMER, Chandigarh)

  • Kataria Gold Medal for Best Post Graduate student of year 2009
  • Bruce Davis Gold Medal in Palliative Medicine 2007 (Bruce Davis Gold Medal in Palliative medicine is given to a junior doctor following a screening test and final exam conducted at National level by the Institute of Palliative Medicine, Kozhikode, Kerala)

 

MBBS (2000-2006, Seth GSMC & KEMH, Mumbai)

  • Dr L H Hiranandani prize for highest marks in subject of ENT (OCT-2003)
  • Dr V G Rao 1st prize for highest marks in subject of P.S.M (OCT-2003)
  • Dr G W Kane Memorial prize for highest marks in subject of Surgery (OCT-2004)
  • Dr R H Karmarkar Gold medal for standing first in General Surgery (OCT-2004)
  • Dr N D Patel Medicine Prize for highest marks in subject of Medicine (OCT-2004)
  • H.Sir Jaswant Singhji Limbdi Prize for highest aggregate marks at 3rd MBBS (OCT-2004)

Head and Neck Cancer

  1. Patil V, Noronha V, Dhumal SB, et al.
    Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial. 
  2. Patil VM, Noronha V, Joshi A, et al.
    Phase I/II Study of Palliative Triple Metronomic Chemotherapy in Platinum-Refractory/Early-Failure Oral Cancer.
  3. Patil VM, Noronha V, Joshi A, et al. A prospective
    randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck.
  4. Joshi A, Patil VM, Noronha V, et al.
    Results of a phase II randomized controlled clinical trial comparing efficacy of cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancer.
  5. Noronha V, Patil VM, Joshi A, al.
    Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer.
  6. Patil VM, Noronha V, Joshi A, et al. A
    randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer.
  7. Noronha V, Joshi A, Patil VM, et al.
    Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial.
  8. Patil VM, Joshi A, Noronha V, et al.
    Technically unresectable recurrent oral cancers: Is NACT the answer?
  9. Patil VM, Noronha V, Joshi A, et al.
    Neoadjuvant chemotherapy in geriatric head and neck cancers.
  10. Patil VM, Chougule A, Noronha V, et al.
    DPYD Mutation in Indian Patients.
  11. Patil VM, Noronha V, Thiagarajan S, et al.
    Salvage surgery in head and neck cancer: Does it improve outcomes?
  12. Patil VM, Joshi A, Noronha V, et al.
    Neoadjuvant Chemotherapy in Locally Advanced and Borderline Resectable Nonsquamous Sinonasal Tumors (Esthesioneuroblastoma and Sinonasal Tumor with Neuroendocrine Differentiation).
  13. Patil VM, Prabhash K, Noronha V, et al.
    Neoadjuvant chemotherapy followed by surgery in very locally advanced technically unresectable oral cavity cancers.

 

Thoracic Tumors

  1. Patil VM, Noronha V, Joshi A, et al.
    Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma.
  2. Noronha V, Patil VM, Joshi A, et al.
    Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer.
  3. Patil V, Noronha V, Joshi A, et al.
    Phase III Non-inferiority Study Evaluating Efficacy and Safety of Low Dose Gemcitabine Compared to Standard Dose Gemcitabine With Platinum in Advanced Squamous Lung Cancer.
  4. Patil V, Joshi A, Noronha V, et al,
    Randomized phase 3 open label study of quality of life of patients on Pemetrexed versus Erlotinib as maintenance therapy for advanced non squamous non EGFR mutated non small cell lung cancer.
  5. Noronha V, Ramaswamy A. Patil VM, et al.
    ALK Positive Lung Cancer: Clinical Profile, Practice and Outcomes in a Developing Country.
  6. Joshi A, Pande N, Noronha V, et al.
    ROS1 mutation non-small cell lung cancer-access to optimal treatment and outcomes.
  7. Joshi AP, Chandrakanth MV, Noronha V, et al.
    Ceritinib in anaplastic lymphoma kinase-positive nonsmall cell lung cancer among patients who were previously exposed to crizotinib: Experience from the Indian subcontinent.
  8. Noronha V, Talreja VT, Patil V, et al.
    Real-World Experience of Patients with Inoperable, Stage III Non-small-Cell Lung Cancer Treated with Durvalumab after Chemoradiotherapy: Indian Experience.
  9. Kate S, Chougule A, Joshi A, et al.
    Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis.
  10. Noronha V, Choughule A, Patil VM, et al.
    Epidermal growth factor receptor exon 20 mutation in lung cancer: types, incidence, clinical features and impact on treatment.

 

Neuro-Oncology

  1. Noronha V, Patil V, Ostwal V, et al.
    Role of paclitaxel and platinum-based adjuvant chemotherapy in high-risk penile cancer.
  2. Patil VM, Noronha V. Joshi A, et al.
    Palliative chemotherapy in carcinoma penis: Does platinum and taxane combination holds a promise?
  3. Noronha V, Abraham G, Patil V, et al.
    A real-world data of Immune checkpoint inhibitors in solid tumors from India.
  4. Ramaswamy A, Joshi A, Noronha V, et al.
    Patterns of Care and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma- Results From a Tertiary Cancer Center in India.
  5. Joshi A, Ramaswamy A, Noronha V, et al.
    Efficacy and safety of sorafenib in advanced renal cell cancer and validation of Heng criteria.
  6. Zanwar S, Joshi A, Noronha V, et al.
    Patterns of care and outcomes for second-line targeted therapy in metastatic renal cell carcinomas: A registry based analysis.
  7. Joshi A, Agarwala V, Ramaswamy A, et al.
    Initial experience with first-line pazopanib in the treatment of metastatic renal cell carcinoma: A single institution data.
  8. Krishna VM, Noronha V, Prabhash K, et al.
    Sunitinib in metastatic renal cell carcimoma: a single-center experience.
  9. Ramaswamy A, Joshi A, Noronha V, et al.
    Poor Risk Advanced Renal Cell Carcinoma: Outcomes from a Registry in a Tertiary Cancer Center.
  10. Agarwala V, Ramaswamy A, Joshi A, et al.
    Treatment outcomes of metastatic nonclear cell renal cell carcinoma: A single institution retrospective analysis.
  11. Noronha V, Joshi A, Muddu VK, et al.
    Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer: Retrospective Data Analysis from an Indian Centre.

 

Uro-Oncology

  1. Noronha V, Patil V, Ostwal V, et al.
    Role of paclitaxel and platinum-based adjuvant chemotherapy in high-risk penile cancer.
  2. Patil VM, Noronha V, Joshi A, et al.
    Palliative chemotherapy in carcinoma penis: Does platinum and taxane combination holds a promise?
  3. Noronha V, Abraham G, Patil V, et al.
    A real-world data of Immune checkpoint inhibitors in solid tumors from India.
  4. Ramaswamy A, Joshi A, Noronha V, et al.
    Patterns of Care and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma- Results From a Tertiary Cancer Center in India.
  5. Joshi A, Ramaswamy A, Noronha V, et al.
    Efficacy and safety of sorafenib in advanced renal cell cancer and validation of Heng criteria.
  6. Zanwar S, Joshi A, Noronha V, et al.
    Patterns of care and outcomes for second-line targeted therapy in metastatic renal cell carcinomas: A registry based analysis.
  7. Joshi A, Agarwala V, Ramaswamy A, et al.
    Initial experience with first-line pazopanib in the treatment of metastatic renal cell carcinoma: A single institution data.
  8. Krishna VM, Noronha V, Prabhash K, et al.
    Sunitinib in metastatic renal cell carcimoma: a single-center experience.
  9. Ramaswamy A. Joshi A, Noronha V, et al.
    Poor Risk Advanced Renal Cell Carcinoma: Outcomes from a Registry in a Tertiary Cancer Center.
  10. Agarwala V, Ramaswamy A, Joshi A, et al.
    Treatment outcomes of metastatic nonclear cell renal cell carcinoma: A single institution retrospective analysis.
  11. Noronha V, Joshi A, Muddu VK, et al. Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer: Retrospective Data Analysis from an Indian Centre.

 

Gyn-Oncology

  1. Dessai SB, Chakraborty S, Babu T, et al.
    Tolerance of weekly paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin.
  2. Chakraborty S, Geetha M, Dessai S, Patil VM.
    How well do elderly patients with cervical cancer tolerate definitive radiochemotherapy using RapidArc? Results from an institutional audit comparing elderly versus younger patients.
  3. Dessai SB, Balasubramanian S, Patil VM, et al.
    Pelvic exenteration: experience from a rural cancer center in developing world.

 

Breast cancer

  1. Bajpai J, Susan D, Patil V, et al.
     Taxane Combination Chemotherapy in Breast Cancer: Experience from a Tertiary Cancer Centre in India.

 

Supportive Care

  1. Patil V, Singhai P, Noronha V, et al.
    Effect of Early Palliative Care on Quality of Life of Advanced Head and Neck Cancer Patients: A Phase III Trial.
  2. Patil VM, Chakraborty S, Bhattacharjee A, Dessai S.
    Survey of the State of Implementation of the American Society of Clinical Oncology/Oncology Nursing Society Safety Standards for Chemotherapy Administration in India.
  3. Patil V, Noronha V, Joshi A, et al.
    Survey of Implementation of Antiemetic Prescription Standards in Indian Oncology Practices and Its Adherence to the American Society of Clinical Oncology Antiemetic Clinical Guideline.
  4. Patil VM, Noronha V. Joshi A, et al.
    Adherence to and Implementation of ASCO Antiemetic Guidelines in Routine Practice in a Tertiary Cancer Center in India.
  5. Patil V, Noronha V, Joshi A, et al.
    Distress Management in Patients With Head and Neck Cancer Before Start of Palliative Chemotherapy: A Practical Approach.
  6. Dessai SB, Chakraborty S, Sajeev Kumar PB, et al.
    Pilot study of single-day distress screening with the NCCN distress thermometer to evaluate the feasibility of routine distress screening in tertiary cancer center in rural India.
  7. Joshi A, Patil VM, Noronha V, et al.
    EMERALD: Emergency visit audit of patients treated under medical oncology in a tertiary cancer center: Logical steps to decrease the burden.

Head & Neck

  1. Long-term outcomes of consecutive patients of oropharyngeal cancer treated with radical radiotherapy
  2. Nutritional status and impact on outcomes of patients with locally advanced head and neck squamous cell carcinoma treated with concurrent chemoradiotherapy: a pre-planned secondary analysis of a phase 3 randomized controlled trial
  3. Long term outcomes of a randomized controlled clinical trial comparing the efficacy of Cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancer. 
  4. Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study. 
  5. Proposed sub- compartmentalisation of high infratemporal fossa involvement in gingivobuccal cancers and its impact on clinical outcome and AJCC 8th edition. A narrative review. 
  6. Long term toxicity and tolerance of concurrent docetaxel with radiotherapy in cisplatin-ineligible head and neck cancer patients. 
  7. Anaplastic Cancer: Our Experience. 
  8. Change in Pattern of Failure in Head and Neck Cancer. 
  9. Non-surgical Organ preservation in Laryngeal and Hypopharyngeal Cancers: An audit from the clinic. 
  10. Prognostic value of radiological extranodal extension (rENE) detected by computed tomography (CT) for predicting outcomes in locally advanced head and neck squamous cell cancer (LAHNSCC) patients treated with radical concurrent chemoradiotherapy (CCRT). 
  11. Real-world data of use of nivolumab in platinum refractory head and neck cancers. 
  12. Real world evidence for use of NACT in locally advanced external auditory canal cancer. 
  13. Real world data of neoadjuvant and adjuvant chemotherapy in head neck osteosarcoma: Experience from a tertiary care center in India. 
  14. Metronomic systemic PCm (paclitaxel, carboplatin + metronomic) neoadjuvant chemotherapy in head and neck cancer. 
  15. A retrospective analysis of patients administered neoadjuvant chemotherapy (NACT) with paclitaxel plus carboplatin with oral metronomic chemotherapy (OMCT) in locally advanced borderline resectable/technically unresectable head and neck cancers. 
  16. Phase III randomized control study evaluating adjuvant metronomic chemotherapy in locally advanced head and neck cancers post-radical chemoradiation (MACE-CTRT). 
  17. 1-s2.0-S1368837522001051-main
  18. PO-1094 Long term outcomes of 630 consecutive patients of oropharyngeal cancer treated with radiotherapy. 
  19. Safety and efficacy of pembrolizumab with chemotherapy in locally advanced head and neck cancers. 
  20. Atypical posterior reversible encephalopathy syndrome associated with Lenvatinib therapy in a patient with metastatic thyroid cancer—A case report. 
  21. Quality of life in patients with locally advanced head and neck squamous cell carcinoma undergoing concurrent chemoradiation with once-a-week versus once-every-3- weeks cisplatin. 
  22. Prognostic and predictive roles of cancer stem cell markers in head and neck squamous cell carcinoma patients receiving chemoradiotherapy with or without nimotuzumab. 
  23. Hypomagnesemia in patients with locally advanced head and neck cancer treated weekly cisplatin-incidence and impact on outcomes. 
  24. Post hoc analysis of the screening log of phase III investigator‑initiated randomized clinical trial comparing palliative oral metronomic versus intravenous chemotherapy in head‑and‑neck cancer. 
  25. Prospective Phase II Open-Label Randomized Controlled Trial to Compare Mandibular Preservation in Upfront Surgery With Neoadjuvant Chemotherapy Followed by Surgery in Operable Oral Cavity Cancer. 
  26. Efficacy and safety of neoadjuvant chemotherapy (NACT) with paclitaxel plus carboplatin and oral metronomic chemotherapy (OMCT) in patients with technically unresectable oral squamous cell carcinoma (OSCC). 
  27. Diclofenac versus tramadol for mucositis related pain in head and neck cancer patients undergoing concurrent chemoradiation – a phase 3 study
  28. Concurrent chemoradiotherapy for locally advanced unresectable adenoid cystic carcinoma of head and neck: experience from a single institute. 
  29. Audit of Demographics, Treatment Patterns and Outcomes of Differentiated Thyroid Cancers Treated with Tyrosine Kinase Inhibitors. 
  30. Weight loss and its impact on outcome in head and cancer patients during chemo-radiation. 
  31. Delirium and seizures in a patient with head-and-neck squamous cell carcinoma on docetaxel, cisplatin, and 5-fluorouracil. 
  32. The efficacy of low-dose immunotherapy in head-and-neck cancer
  33. Quality of life without toxicity or symptoms analysis of a randomized controlled clinical trial comparing efficacy of cabazitaxel versus docetaxel in recurrent head and neck cancer
  34. Adding to the debate on once-a-week versus once-every-3-weeks cisplatin dosing in concurrent chemoradiotherapy for locally advanced head and neck squamous cell cancer
  35. Quality of life and quality-adjusted time without toxicity in palliatively treated head-and-neck cancer patients
  36. Distress Management in Patients With Head and Neck Cancer Before Start of Palliative Chemotherapy: A Practical Approach
  37. Long-term survival outcomes of technically unresectable carcinoma maxilla postinduction chemotherapy
  38. Influence of Hypothyroidism After Chemoradiation on Outcomes in Head and Neck Cancer
  39. Toxicity and tolerance of concurrent docetaxel with radiotherapy in cisplatin ineligible head and neck cancer patients.
  40. Results of a randomized phase III study of nimotuzumab in combination with concurrent radiotherapy and cisplatin versus radiotherapy and cisplatin alone, in locally advanced squamous cell carcinoma of the head and neck.
  41. Quality of life in patients with locally advanced head and neck cancer treated with concurrent chemoradiation with cisplatin and nimotuzumab versus cisplatin alone – Additional data from a phase 3 trial. 
  42. Aspiration pneumonia in head and neck cancer patients undergoing concurrent chemoradiation from India: Findings from a post hoc analysis of a phase 3 study. 
  43. 910P Repurposing pantoprazole in advanced head and neck squamous cell carcinoma: A phase I/II randomized study. 
  44. 865MO RMAC study: A randomized study evaluating the efficacy of metronomic adjuvant chemotherapy in patients with recurrent head and neck cancers post salvage surgery, not eligible for re-irradiation. 
  45. An Audit of Systemic Therapy in Medullary Carcinoma Thyroid. 
  46. Systemic Therapy in Thyroid Cancer. 
  47. Advances in pharmacotherapy for head and neck cancer. 
  48. Post hoc analysis of a randomized controlled trial comparing concurrent chemoradiation with cisplatin versus nimotuzumab-cisplatin, focusing on acute oral mucositis. 
  49. Outcome of neoadjuvant chemotherapy (NACT) with paclitaxel plus carboplatin and oral metronomic chemotherapy (OMCT) in patients with technically unresectable oral cavity squamous cell carcinoma (SCC). 
  50. Aprepitant for patients with head-and-neck cancer receiving once-a-week cisplatin with radiation: Is it required?. 
  51. Correlation of transcriptionally active human papillomavirus status with the clinical and molecular profiles of head and neck squamous cell carcinomas. 
  52. Intensity‐modulated radiation therapy for nasal cavity and paranasal sinus tumors: Experience from a single institute. 
  53. The Pattern of Care of Use of Nivolumab in Head and Neck Cancers – Audit From a Tertiary Cancer Centre. 
  54. Oral metronomic therapy in head and neck cancer – Authors’ reply. 
  55. FGFR alterations in head-and-neck cancer. 
  56. SAFETY AND EFFICACY OF CONCURRENT CHEMORADIOTHERAPY FOR HEAD-AND-NECK CANCERS IN OLDER VERSUS YOUNGER PATIENTS: POST HOC ANALYSIS OF A RANDOMISED CONTROLLED TRIAL. 
  57. Chemoradiation in Unresectable Oral Cavity Cancer: A Myth or Reality!. 
  58. Safety and efficacy of concurrent chemoradiotherapy for head-and-neck cancers in older versus younger patients: Post hoc analysis of a randomized controlled trial. 
  59. Prognostic and predictive significance of nuclear HIF1α expression in locally advanced HNSCC patients treated with chemoradiation with or without nimotuzumab. 
  60. Molecular tumor board: Case 4 Salivary Gland Cancer: Novel therapeutic options as a result of comprehensive molecular profiling. 
  61. Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial. 
  62. Articles Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel- group, non-inferiority, randomised, phase 3 trial. 
  63. Long‑term outcomes of locally advanced and borderline resectable esthesioneuroblastoma and sinonasal tumor with neuroendocrine differentiation treated with neoadjuvant chemotherapy. 
  64. Beyond conventional chemotherapy, targeted therapy and immunotherapy in squamous cell cancer of the oral cavity. 
  65. Incidence and Outcome of Second Malignancy in Primary Treated Head and Neck Cancer. 
  66. Salvage surgery in head and neck cancer: Does it improve outcomes?. 
  67. Indication of adjuvant chemoradiation post neoadjuvant chemotherapy in very locally advanced borderline resectable head and neck cancer. 
  68. Optimal cumulative cisplatin dose for radio-sensitization in locally advanced head and neck cancer. 
  69. Hypothyroidism and its impact on outcomes in head and neck cancer. 
  70. A phase III randomized clinical trial of diclofenac versus tramadol for mucositis-related pain in head and neck cancer patients undergoing concurrent chemoradiation. 
  71. Incidence of 5-fluorouracil related in cardiotoxicity in patients with head and neck cancer. 
  72. Second malignancy post-chemoradiation in head and neck cancer patients. 
  73. Results of a phase II randomized controlled clinical trial comparing efficacy of Cabazitaxel versus Docetaxel as second line or above therapy in recurrent head and neck cancer.
  74. Evolving role of immunotherapy in head-and-neck cancers: A systemic review.
  75. Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial.
  76. Current and Emerging Role of Chemotherapy in Oral Cancer.
  77. Retrospective analysis of palliative metronomic chemotherapy in head and neck cancer.
  78. 343PQTWiST analysis to compare the benefit of Metronomic chemotherapy versus intravenous cisplatin for patients with Head and neck cancer.
  79. 337OQuality of life without toxicity or symptoms analysis of a randomized controlled clinical trial comparing efficacy of Cabazitaxel versus docetaxel in recurrent Head and Neck Cancer.
  80. 342PQOL analysis of a phase II randomized controlled clinical trial comparing efficacy of cabazitaxel versus docetaxel as second line or above therapy in recurrent head and neck cancer.
  81. Results of a phase II randomized controlled clinical trial comparing efficacyof Cabazitaxel versus Docetaxel as second line or above therapy in recurrent head and neck cancer.
  82. 1098PIncidence and impact of DPD mutation on neoadjuvant chemotherapy in head and neck cancers.
  83. Phase III randomized trial comparing weekly versus three-weekly (W3W) cisplatin in patients receiving chemoradiation for locally advanced head and neck cancer.
  84. Results of a phase II randomized controlled clinical trial comparing efficacy of cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancer.
  85. Incidence and impact of Dihydropyrimidine dehydrogenase gene mutation on neoadjuvant chemotherapy in head and neck cancers.
  86. Carboplatin-based concurrent chemoradiation therapy in locally advanced head and neck cancer patients who are unfit for cisplatin therapy.
  87. Neoadjuvant chemotherapy in geriatric head and neck cancers.
  88. Role of neoadjuvant chemotherapy in advanced carcinoma of the hypopharynx and larynxLetter to the Editor.
  89. A tertiary care experience with paclitaxel and cetuximab as palliative chemotherapy in platinum sensitive and nonsensitive in head and neck cancers.
  90. Expectations and preferences for palliative chemotherapy in head and neck cancers patients.
  91. 386P Expectations and preferences for palliative chemotherapy in head and neck cancers patients.
  92. Toxicity analysis of docetaxel, cisplatin, and 5-fluorouracil neoadjuvant chemotherapy in Indian patients with head and neck cancers.
  93. Dihydropyrimidine dehydrogenase mutation in neoadjuvant chemotherapy in head and neck cancers: Myth or reality?.
  94. Preoperative Chemotherapy and Metronomic Scheduling of Chemotherapy in Locally Advanced Oral Cancers.
  95. Response to docetaxel and cisplatin induction chemotherapy of locally advanced head and neck squamous cell carcinoma: a multicenter, non-comparative, open-label interventional pilot study.
  96. Toxicity, tolerance and outcomes of carboplatin based CTRT ( concurrent chemoradiation) in head and neck cancers in patients who were not fit for cisplatin based CTRT.
  97. Time-Dependent Area under the ROC Curve for Optimum Biological Dose Detection.
  98. An audit of the results of a triplet metronomic chemotherapy regimen incorporating a tyrosine kinase inhibitor in recurrent/metastatic head and neck cancers patients.
  99. Health-related quality of life in patients with metastatic, relapsed, or inoperable squamous cell carcinoma of the head and neck in India.
  100. Outcome of operable oral cavity cancer and impact of maintenance metronomic chemotherapy: A retrospective study from rural India.
  101. Metronomic palliative chemotherapy in maxillary sinus tumor.
  102. Efficacy of second‑line erlotinib in patients postprogression of first‑line chemotherapy in head and neck cancers.
  103. Technically unresectable recurrent oral cancers: Is NACT the answer?.
  104. Head and neck cancer in geriatric patients: Analysis of the pattern of care given at a tertiary cancer care center.
  105. Cisplatin based adjuvant chemoradiation following neoadjuvant chemotherapy and surgery in advanced oral cavity cancers: A deliverable regimen?.
  106. Molecular biology of head and neck cancers.
  107. Chemoprevention in head and neck cancer.
  108. Extra-lymphatic filariasis at reconstructive surgery flap site recurrence of head and neck cancer.
  109. Neoadjuvant chemotherapy and surgical margin in technically unresectable buccal mucosa cancers.
  110. Compliance With Neoadjuvant Chemotherapy in T4 Oral Cancers: Place, Person, Socioeconomic Status, or Assistance.
  111. Neoadjuvant chemotherapy in advanced sinonasal teratocarcinosarcoma with intracranial extension: Report of two cases with literature review.
  112. Does the use of induction chemotherapy in oral cavity cancer compromise subsequent loco-regional treatment delivery: Results from a matched pair analysis.
  113. Neoadjuvant Chemotherapy in Technically Unresectable Oral Cancers: Does Human Papillomavirus Make a Difference?.
  114. Neoadjuvant chemotherapy in technically unresectable carcinoma of external auditory canal.
  115. Metronomic chemotherapy in platinum-insensitive failures and/or early failures postmultimodality management in oral cancers.
  116. NACT in locally advanced oral cancers : Does HPV make a difference?.
  117. Compliance to NACT in T4 oral cancers :The place, person, socioeconomic status or assistance.
  118. Effect of early integration of specialized palliative care into standard oncologic treatment on the quality of life of patients with advanced head and neck cancers: A phase III randomized controlled trial. 
  119. Quality of life in patients with locally advanced head and neck cancer undergoing chemoradiation with once-a-week versus once-every-three-weeks cisplatin. 
  120. Low-cost oral metronomic versus intravenous chemotherapy in recurrent, inoperable and metastatic head and neck cancer: Phase III Metro-CIS study. 
  121. Prognostic value of radiological extranodal extension detected by computed tomography for predicting outcomes in head and neck squamous cell cancer patients treated with radical chemoradiotherapy. 
  122. A prospective phase II open-label randomized controlled trial to compare mandibular preservation in upfront surgery to neoadjuvant chemotherapy followed by surgery in operable oral cavity cancer. 
  123. Aprepitant in weekly cisplatin with radiation in head and neck cancer: Is it required?. 
  124. Efficacy and safety of neoadjuvant chemotherapy (NACT) with paclitaxel plus carboplatin and oral metronomic chemotherapy (OMCT) in patients with technically unresectable oral cavity squamous cell carcinoma (SCC). 
  125. Should we wait or not? The preferable option for patients with stage IV oral cancer in COVID-19 pandemic. 
  126. Clinical outcomes for nasopharyngeal cancer with intracranial extension after taxane-based induction chemotherapy and concurrent chemo-radiotherapy in the modern era. 
  127. Indian clinical practice guideline for the management of hypopharyngeal carcinoma: A consensus statement. 
  128. Indian clinical practice guideline for the management of nasopharyngeal carcinoma: A consensus statement. 
  129. Indian clinical practice guideline for the management of squamous cell carcinoma of head and neck: A consensus statement. 
  130. Indian clinical practice guideline for the management of oral cavity cancer: A consensus statement. 
  131. Indian clinical practice guideline for the management of oropharyngeal carcinoma: A consensus statement. 
  132. Indian clinical practice guideline for the management of laryngeal carcinoma: A consensus statement. 
  133. Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer. 
  134. Palliative chemotherapy in head and neck cancer: balancing between beneficial and adverse effects. 
  135. The pattern of care in head-and-neck cancer: Comparison between before and during the COVID-19 pandemic. 
  136. Effect of Early Palliative Care on the Quality of Life of Patients with Advanced Head and Neck Cancers: A Phase 3 Randomized Controlled Trial. 
  137. Palliative oral triple metronomic chemotherapy in a patient with head-and-neck cancer during the COVID-19 pandemic in India: A case report. 
  138. Patterns of failure and outcomes in cT4 Oral squamous cell carcinoma (OSCC) undergoing upfront surgery in comparison to Neo-Adjuvant Chemotherapy (NACT) followed by surgery: A Matched Pair analysis. 
  139. DOES AGE MATTER FOR RADICAL CHEMORADIATION IN HEAD AND NECK CANCER: A POST-HOC ANALYSIS OF A RANDOMIZED STUDY. 
  140. 288OMolecular profiling and treatment patterns of advanced salivary gland cancers in head and neck region. 
  141. 1121PNimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV-negative oropharyngeal cancer. 
  142. Phase I/II Study of Palliative Triple Metronomic Chemotherapy in Platinum-Refractory/ Early-Failure Oral Cancer. 
  143. A Randomized Phase 3 Trial Comparing Nimotuzumab Plus Cisplatin Chemoradiotherapy Versus Cisplatin Chemoradiotherapy Alone in Locally Advanced Head and Neck Cancer. 
  144. Taxane-based Induction Chemotherapy Plus Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma: Prospective Results from a Non-endemic Cohort. 
  145. NUT Midline Carcinoma. 
  146. Nimotuzumab Dosing and Outcomes in Locally Advanced Head and Neck Cancer. 
  147. Palliative chemotherapy in carcinoma nasopharynx. 
  148. A-prospective-randomized-phase-II-study-comparing-metronomic-chemotherapy-with-chemotherapy-single-agent-cisplatin-in-patients-with-metastatic-relapse.
  149. Excellent response to oral Metronomic chemotherapy in unresectable adenocarcinoma of external auditory canal.
  150. Does DeCIDE Give a Decisive Answer Against Induction Chemotherapy in Head and Neck Cancers?.
  151. Locoregional recurrences after postoperative Volumetric Modulated Arc Radiotherapy (VMAT) in oral cavity cancers in a resource constrained setting : experience and lessons learned.
  152. A prospective randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck.
  153. Is taxane/platinum/5 fluorouracil superior to taxane/platinum alone and does docetaxel trump paclitaxel in induction therapy for locally advanced oral cavity cancers?.
  154. Neoadjuvant chemotherapy followed by surgery in very locally advanced technically unresectable oral cavity cancers.
  155. How safe is adjuvant RapidArc in Oral Cavity Cancers: An analysis of Marginal and Outfield Failures.
  156. Recurrent sinonasal teratocarcinosarcoma with intracranial extension: Case report.
  157. Weekly chemotherapy as Induction chemotherapy in locally advanced head and neck cancer for patients ineligible for 3 weekly maximum tolerable dose chemotherapy.
  158. Tolerance and toxicity of neoadjuvant docetaxel, cisplatin and 5 fluorouracil regimen in technically unresectable oral cancer in resource limited rural based tertiary cancer center.
  159. A phase II study comparing metronomic chemotherapy with chemotherapy (single-agent cisplatin), in patients with metastatic, relapsed, or inoperable squamous cell carcinoma of head and neck.
  160. Neoadjuvant chemotherapy in very locally advanced technically unresectable oral cavity cancers.
  161. Induction Chemotherapy in Technically Unresectable Locally Advanced Carcinoma of Maxillary Sinus.
  162. PCN157. Health Related Quality of Life in Patients with Metastatic, Relapsed, or Inoperable Squamous Cell Carcinoma of the Head and Neck in India.
  163. Guidelines for treatment of recurrent or metastatic head and neck cancer.
  164. Referral pattern for neoadjuvant chemotherapy in the head and neck cancers in a tertiary care center.
  165. Is there a role of induction chemotherapy followed by resection in T4b oral cavity cancers?.
  166. Comparison of concomitant boost radiotherapy against concurrent chemoradiation in locally advanced oropharyngeal cancers: A phase III randomised trial.
  167. Induction chemotherapy in technically unresectable locally advanced oral cavity cancers: Does it make a difference?.
  168. Neo-adjuvant chemotherapy in advanced hypopharyngeal carcinoma.
  169. Epidemiology of oral cancers referred for NACT, the demographics, clinical profile, and organ functions.
  170. Are three drugs better than two and does docetaxel trump paclitaxel in induction therapy for locally advanced oral cavity cancers?.
  171. Acute toxicity of neoadjuvant chemotherapy in oral cavity cancers: Can it be predicted?.
  172. OP048: Induction chemotherapy in unresectable oral cavity cancers.
  173. Oral Metronomic Chemotherapy in Recurrent, Metastatic and Locally Advanced Head and Neck Cancers.
  174. Is There a Limitation of RECIST Criteria in Prediction of Pathological Response, in Head and Neck Cancers, to Postinduction Chemotherapy?.
  175. Development of hyponatremia on neoadjuvant chemotherapy in locally advanced head & neck cancers.
  176. Neoadjuvant chemotherapy followed by definitive local treatment in locally advanced carcinoma maxillary sinus.
  177. Palliative chemotherapy in head and neck cancers: A tertiary care center experience with weekly paclitaxel and cetuximab.
  178. Metronomic chemotherapy in advanced oral cancers.
  179. Conformal Radiotherapy in the Treatment of Advanced Juvenile Nasopharyngeal Angiofibroma With Intracranial Extension: An Institutional Experience.
  180. Acute Toxicities Experienced during Simultaneous Integrated Boost Intensity-modulated Radiotherapy in Head and Neck Cancers – Experience from a North Indian Regional Cancer Centre.
  181. Preliminary results of SIB-IMRT in head and neck cancers: Report from a regional cancer center in northern India.
  182. QOL assessment in head and neck cancer patients undergoing neoadjuvant chemotherapy and its impact on overall survival. 
  183. A phase II randomized control trial of erlotinib in combination with celecoxib in patients with operable oral squamous cell carcinoma (OSCC): Erlo-Xib Study. 
  184. Dermatofibrosarcoma protuberans of head and neck: Clinical outcome of nine cases treated with imatinib. 
  185. Genomic Characterization of Papillary Thyroid Cancer Reveals Germline Mutations Associated With Congenital Hypothyroidism
  186. Triple Oral Metronomic Chemotherapy Versus Chemotherapy of Physician Discretion After Failure of Platinum-Based Therapy in Advanced Head and Neck Cancer: A Phase III Randomized Study (METRO-CHASE Study)
  187. Evaluating the prognostic value of tumor-derived circulating endothelial cells and their progenitors in platinum-refractory oral cancer patients for response to triple metronomic therapy
  188. Outcomes of selective neck dissection in node positive oral cavity squamous cell carcinoma
  189. PD-L1 in Oral Cavity Cancers—Audit for Tertiary Care Center in India
  190. Phase 3 randomized study of physician choice vs metronomic chemotherapy in platinum refractory/ineligible head and neck cancer in palliative setting with survival outcomes
  191. Phase 3 randomized study of physician choice vs metronomic chemotherapy in platinum refractory/ineligible head and neck cancer in palliative setting with survival outcomes
  192. Ewing’s Sarcoma of the Head and Neck: Outcomes of 101 Patients Treated at a Tertiary Cancer Center
  193. Compartmentalization of High Infratemporal Fossa in Oral Cavity Squamous Cell Carcinomas and Its Impact on Clinical Outcome
  194. Nose and sinuses
  195. Indian clinical practice consensus guidelines for the management of nasopharyngeal cancer
  196. Indian clinical practice consensus guidelines for the management of locoregional hypopharyngeal cancer – Update 2023
  197. Comprehensive Genomic Profiling of Anaplastic Thyroid Cancer Identifies Alterations in THRA, a Potential Modifier of Cellular Plasticity
  1. MMAP-08 CHEMO-REIRRADIATION (NORMOFRACTIONATED VS. HYPOFRACTIONATED) WITH OR WITHOUT BEVACIZUMAB IN RECURRENT ADULT DIFFUSE HIGH-GRADE GLIOMA (COBRA): PHASE III RANDOMIZED CONTROLLED TRIAL WITH A 2 X 2 FACTORIAL DESIGN. 
  2. Mebendazole plus lomustine or temozolomide in patients with recurrent glioblastoma: A randomised open-label phase II trial. 
  3. MEDB-27. Clinico-Radiological Outcomes in WNT-pathway Medulloblastoma: Retrospective Single Institutional Audit. 
  4. Efficacy of Gemcitabine in recurrent meningioma: A phase II study. 
  5. High-dose salvage re-irradiation in recurrent/progressive adult diffuse gliomas: development of a novel prognostic scoring system. 
  6. Efficacy and safety of extended adjuvant temozolomide compared to standard adjuvant temozolomide in glioblastoma: Updated systematic review and meta-analysis. 
  7. Diffuse hemispheric glioma, H3G34-mutant: distinctive clinicopathological features. 
  8. Optimizing adjuvant therapy in elderly patients with glioblastoma: single-institution audit of outcomes. 
  9. The prevalence of cognitive impairment in older Indian persons with cancer and brain metastases. 
  10. Prognostic impact of semantic MRI features on survival outcomes in molecularly subtyped medulloblastoma. 
  11. Temozolomide-induced myelotoxicity and single nucleotide polymorphisms in the MGMT gene in patients with adult diffuse glioma: a single-institutional pharmacogenetic study. 
  12. Optimizing Postoperative Adjuvant Therapy in Elderly Patients with Newly Diagnosed Glioblastoma: Single-Institution Audit of Clinical Outcomes from a Tertiary-Care Comprehensive Cancer Center in India. 
  13. Definitive and adjuvant radiation therapy for external auditory canal and temporal bone squamous cell carcinomas: Long term outcomes. 
  14. Cost-Effectiveness of Temozolamide for Treatment of Glioblastoma Multiforme in India. 
  15. Expectation and Preferences with Palliative Systemic Therapy in Recurrent Gliomas
  16. The story of two eyes- What to look for in the patient’s eyes?
  17. A cross-sectional audit of distress in patients undergoing adjuvant therapy or follow-up in central nervous system malignancies
  18. RTHP-01. DOES THE EFFICACY OF SALVAGE RE-IRRADIATION IN RECURRENT MEDULLOBLASTOMA DEPEND UPON RISK-STRATIFICATION, SITE OF RELAPSE, AND MOLECULAR SUBGROUP?
  19. Cross-Sectional Study of Temozolomide-Induced Chemotherapy-Induced Nausea and Vomiting in Patients with Glioma
  20. RONC-17. DOES THE EFFICACY OF SALVAGE RE-IRRADIATION IN RECURRENT MEDULLOBLASTOMA DEPEND UPON RISK-STRATIFICATION, SITE OF RELAPSE, AND MOLECULAR SUBGROUP?
  21. RONC-07. THE TALE OF 100 DIPGs AND RADIOTHERAPY
  22. Shadow study: randomized comparison of clinic with video follow-up in glioma undergoing adjuvant temozolomide therapy
  23. CTNI-34. TOXICITY PROFILE AND COMPLIANCE OF PATIENTS WITH HIGH RISK GRADE 2 OR GRADE 3 GLIOMAS RECEIVING ADJUVANT PCV VERSUS ADJUVANT TEMOZOLOMIDE. 
  24. Brain FET PET tumor‐to‐white mater ratio to differentiate recurrence from post‐treatment changes in high‐grade gliomas. 
  25. Prognostic Impact of Semantic MRI Features on Survival Outcomes in Medulloblastoma: Does It Reflect or Transcend Radiogenomic Correlation?. 
  26. Optimal dose of bevacizumab in recurrent glioma: A retrospective study. 
  27. Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy. 
  28. High-dose Salvage Re-irradiation in Recurrent/progressive Adult Diffuse High-Grade Glioma: Development of a Novel Prognostic Scoring System. 
  29. The prevalence of cognitive impairment in older Indian persons with cancer and brain metastases. 
  30. MGMT gene polymorphisms in patients with severe hematological toxicity treated with temozolomide for adult diffuse gliomas: Results from a tertiary-care comprehensive cancer center. 
  31. Clinical Audit of Survival Outcomes and Prognostic Factors in Adolescents and Adults with Medulloblastoma. 
  32. Cancer-related fatigue and its impact on quality of life in patients with central nervous system tumors: A cross-sectional analysis. 
  33. Safety and efficacy of concurrent carboplatin during full-dose craniospinal irradiation for high-risk/metastatic medulloblastoma in a resource-limited setting. 
  34. High-dose salvage re-irradiation for recurrent/progressive adult diffuse glioma: healing or hurting?. 
  35. Safety and efficacy of bevacizumab biosimilar in recurrent/ progressive glioblastoma. 
  36. Financial toxicities in patients receiving systemic therapy for brain tumors: A cross-sectional study. 
  37. Thromboembolic events in brain tumour patients on bevacizumab. 
  38. Multidisciplinary brain metastasis clinic: is it effective and worthwhile?. 
  39. A Survey of Satisfaction with Treatment among Brain Tumor Patients. 
  40. Gemcitabine in Recurrent Meningioma. 
  41. 391P Cognitive impairment in primary brain tumour patients receiving systemic therapy: A cross-sectional study. 
  42. Cognitive score in patients with primary brain tumors undergoing systemic therapy – a cross-sectional study. 
  43. SPIRITUAL WELL-BEING IN BRAIN TUMOUR PATIENTS -AN INSIGHT. 
  44. Financial toxicity in patients undergoing systemic therapy in brain tumours: A cross-sectional study. 
  45. Prospective Longitudinal Assessment of Quality of Life and Activities of Daily Living as Patient-Reported Outcome Measures in Recurrent/ Progressive Glioma Treated with High-dose Salvage Re-irradiation. 
  46. 390P Spiritual well-being in brain tumour patients: An insight. 
  47. Extended adjuvant temozolomide in newly diagnosed glioblastoma: Is more less?. 
  48. Melanotic Schwannoma, a Deceptive Misnomer for a Tumor With Relative Aggressive Behavior: A Series of 7 Cranial and Spinal Cases. 
  49. Safety and efficacy of bevacizumab biosimilar in glioma. 
  50. Reverse swing‐M, phase 1 study of repurposing mebendazole in recurrent high‐grade glioma. 
  51. Differentiating dural metastases from meningioma: role of 68Ga DOTA-NOC PET/CT. 
  52. Coronavirus disease 2019 pandemic and its implications on triaging patients with brain tumors for surgery, radiotherapy, and chemotherapy. 
  53. P09.03 Bevacizumab in glioma: An experience from Tata Memorial Hospital
  54. Rechallenge temozolomide in glioma: A case series from India
  55. A case series of salvage CCNU in high-grade glioma who have previously received temozolomide from a tertiary care institute in Mumbai
  56. Neoadjuvant Chemotherapy in Locally Advanced and Borderline Resectable Nonsquamous Sinonasal Tumors (Esthesioneuroblastoma and Sinonasal Tumor with Neuroendocrine Differentiation)
  57. PMultidisciplinary brain metastasis clinic: Is it effective and worthwhile?. 
  58. PPattern of care in high-grade gliomas after recurrence. 
  59. Shielding in whole brain irradiation in the multileaf collimator era: Dosimetric evaluation of coverage using SFOP guidelines against in-house guidelines
  60. Outcomes of salvage re-irradiation in recurrent medulloblastoma correlate with age at initial diagnosis, primary risk-stratification, and molecular subgrouping. 
  61. An exceptional response to nivolumab in relapsed and refractory malignant mesothelioma. 
  62. Neoadjuvant chemotherapy in technically unresectable adenocarcinoma of parotid. 
  63. EP-1235 Response to re-RT helps deciding dose and predicts survival in Diffuse Intrinsic Pontine Glioma. 
  1. Long-Term Outcomes of Crizotinib Treated ALK-Positive Lung Cancer Patients: A Retrospective Audit of Prospective Data from Resource-Constrained Settings
  2. EP08.03-002 Local Ablative Therapy in Oligoprogressive NSCLC – Results from a Tertiary Cancer Center of India
  3. Lung cancer with dual EGFR and ALK driver alterations at baseline: a retrospective observational cohort study
  4. Characteristics and clinical outcomes of pulmonary sarcomatoid carcinoma: experience from Tata Memorial Centre
  5. Leptomeningeal metastasis from non-small cell lung cancer – a post-hoc analysis from four randomised clinical trials
  6. ALK-positive advanced non-small cell lung cancer patients with poor performance status: Outcomes in a real-world scenario
  7. Phase III randomized controlled trial comparing chemotherapy to best supportive care in advanced esophageal and gastroesophageal junction cancer.
  8. Five years survival outcomes of head and neck cancer patients treated with palliative metronomic chemotherapy.
  9. Checkpoint inhibitor accessibility in 15,000+ Indian patients.
  10. Long-term outcomes of a randomized controlled clinical trial comparing the efficacy of cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancer.
  11. Oral metronomic chemotherapy after definitive chemoradiation in esophageal squamous cell carcinoma: a randomized clinical trial
  12. Small cell carcinoma of the oesophagus: experience of an Indian Tertiary Cancer Centre
  13. Treatment pattern and outcomes in de novo T790M-mutated non-small cell lung cancer
  14. Tackling brain metastases from lung cancer during the COVID‐19 pandemic
  15. Clinical Utility of Liquid Biopsy (Cell-free DNA) Based EGFR Mutation Detection Post treatment Initiation as a Disease Monitoring Tool in Patients With Advanced EGFR-mutant NSCLC
  16. Prognostic Impact of Baseline Liver Metastasis in ALK Fusion-Positive Metastatic Lung Cancer: A Retrospective Review
  17. EGFR exon 20 insertion in non-small cell lung cancer
  18. Molecular tumor board: Case 1-Interplay of EGFR, MET and PD-L1 in non-small cell lung carcinoma
  19. Desperate times, desperate measures: Low-dose nivolumab-induced remission in relapsed NSCLC
  20. LBA10A randomized investigator initiated phase III study comparing low dose gemcitabine to standard dose gemcitabine with platinum in advanced squamous non driver mutated non-small cell lung cancer
  21. 529PThe management and outcome of crizotinib resistant patients: Comparison of patients who received ceritinib to those treated with chemotherapy or other oral TKI
  22. Thromboembolic events in patients with advanced stage non-small cell lung cancer treated with platinum-based chemotherapy: A prospective observational study
  23. P2-122Retrospective study to evaluate treatment outcomes of Pleural Mesothelioma treated in a tertiary care centre from India
  24. MA02.07 Aprepitant for Cough Suppression in Advanced Lung Cancer: A Randomized Trial
  25. P2.01-54 Predictive Factors for Thromboembolism in Advanced Lung Cancer Patients on Platinum Chemotherapy: A Prospective Study
  26. P1.01-44 Outcome of Uncommon EGFR Mutation Positive Newly Diagnosed Advanced NSCLC Patients: A Single-Centre Retrospective Analysis
  27. Tyrosine Kinase Inhibitor versus Physician Choice Chemotherapy in Second-Line Epidermal Growth Factor Receptor Mutation Non-Small Cell Lung Cancer: Post hoc Analysis of Randomized Control Trial
  28. Sequential treatment with alectinib in crizotinib-resistant non-small-cell lung cancer
  29. Quality of life analysis of Pemetrexed versus Erlotinib maintenance in EGFR mutation negative advanced non small cell lung cancer.
  30. Impact of imaging based sarcopenia and modified advanced lung cancer inflammation index (mALI) on clinical outcomes in advanced NSCLC: A occult killer and a prognostic biomarker.
  31. Molecular tumor board–guided treatment of non-small-cell lung cancer with dual driver (ALK and EGFR) alterations
  32. Efficacy and safety of induction weekly paclitaxel and carboplatin in esophageal cancer: A retrospective study
  33. The Epidemiological Trend of Esophageal Cancer in Mumbai, India, Over the Past Fifteen Years
  34. Post-cricoid and Upper Oesophagus Cancers Treated with Organ Preservation Using Intensity-modulated Image-guided Radiotherapy: a Phase II Prospective Study of Outcomes, Toxicity and Quality of Life
  35. An observational study to evaluate factors predicting survival in patients of non-small cell lung cancer with poor performance status in resource-constrained settings
  36. PO-0957 Organ-preservation in Post-Cricoid and Upper-Esophagus (PCUE) cancers: Seeking optimum outcomes
  37. Small Cell Carcinoma Esophagus: Experience of an Indian Tertiary Cancer Center
  38. The epidemiological trend of esophageal cancer in Mumbai, India over the past two decades.
  39. Pulmonary sarcomatoid carcinoma: Retrospective analysis from a single center.
  40. Impact of the geriatric assessment on clinical treatment decision in older Indian persons with cancer.
  41. Molecular characterization of lung squamous cell carcinoma tumors reveals therapeutically relevant alterations
  42. Distress Screening in Head and Neck Cancer Patients Planned for Cancer‐Directed Radiotherapy
  43. Standard maintenance therapy versus local consolidative radiation therapy and standard maintenance therapy in 1-5 sites of oligometastatic non-small cell lung cancer: A study protocol of phase III randomised controlled trial
  44. P76.26 Survival Outcomes in Patients Receiving Second Line Osimertinib Post First Line First Generation TKI Alone or in Combination with Chemotherapy
  45. Validation of a novel causality assessment scale for adverse events in non-small cell lung carcinoma patients treated with platinum and pemetrexed doublet chemotherapy
  46. Protocol for a phase II randomised controlled trial of TKI alone versus TKI and local consolidative radiation therapy in patients with oncogene driver-mutated oligometastatic non-small cell lung cancer
  47. A randomized clinical trial evaluating the efficacy and safety of the addition of oral metronomic chemotherapy after completion of standard chemoradiation versus observation in patients with locally advanced esophageal and gastroesophageal junction squamous cell carcinoma.
  48. An exceptional response to olaparib in relapsed and refractory BRCA2 mutated non-small cell lung cancer in hereditary breast–ovarian cancer syndrome
  49. 165P Analysis of our experience of ROS-1 patients in advanced NSCLC
  50. Lorlatinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: Indian experience
  51. Real-World Experience of Patients with Inoperable, Stage III Non-small-Cell Lung Cancer Treated with Durvalumab after Chemoradiotherapy: Indian Experience
  52. 417P Efficacy and safety of lorlatinib in subsequent lines of therapy in ALK and ROS1 positive lung cancer
  53. 403P Clinical profile, practice pattern and outcomes in ALK-positive lung cancer: Real-world data from India
  54. Safety and CSF distribution of high-dose erlotinib and gefitinib in patients of non–small cell lung cancer (NSCLC) with brain metastases
  55. Systemic therapy for limited stage small cell lung carcinoma
  56. The role of chemotherapy in patients with small cell lung cancer and poor performance status View supplementary material The role of chemotherapy in patients with small cell lung cancer and poor performance status
  57. Resistance mechanisms to epidermal growth factor receptor inhibitors in non-small cell lung cancer
  58. Deep learning-based predictive imaging biomarker model for EGFR mutation status in non-small cell lung cancer from CT imaging.
  59. Leptomeningeal metastasis from non-small cell lung cancer- outcomes from a tertiary care center.
  60. Definitive Radiation Therapy With Dose Escalation Is Beneficial In Patients With Squamous Cell Cancer Of The Esophagus
  61. Aprepitant for Cough Suppression in Advanced Lung Cancer: A Randomized Trial
  62. Stereotactic body radiation therapy for medically inoperable early-stage lung cancer: Tata Memorial Hospital perspective and practice recommendations
  63. Reply to T. Tanaka et al and F. Liang
  64. Third-line therapy in the epidermal growth factor receptor mutation-positive advanced nonsmall-cell lung cancer
  65. Systemic therapy for thoracic malignancies during the COVID-19 pandemic
  66. Radiologic progression in a patient with non-small-cell lung cancer
  67. The efficacy and safety of first-line therapy for the epidermal growth factor receptor mutant non-small cell lung cancer in older versus younger patients: A pooled analysis of two randomized controlled trials
  68. Neurological deterioration in a patient with lung cancer and brain metastasis
  69. Randomized phase 3 open label study of quality of life of patients on Pemetrexed versus Erlotinib as maintenance therapy for advanced non squamous non EGFR mutated non small cell lung cancer
  70. 151P Maintenance therapy using tyrosine kinase inhibitor (erlotinib) or pemetrexed in metastatic/locally advanced in EGFR mutation-negative lung cancer: Comparison of results
  71. 72PD MR imaging radiomics of NSCLC brain metastases: A potential targetable imaging biomarker for EGFR status
  72. Applying the QUARTZ Trial Results in Clinical Practice: Development of a Prognostic Model Predicting Poor Outcomes for Non-small Cell Lung Cancers with Brain Metastases
  73. Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation?
  74. Prognostic value of a patient-reported functional score versus physician-reported Karnofsky Performance Status Score in brain metastases
  75. P3.03-015 ROS-1 Rearranged Non-Small Cell Lung Cancer and Crizotinib: An Indian Experience
  76. P2.03-027 Comparative Longitudinal Toxicity Analysis of EGFR Mutated NSCLC Treated with Either Pemetrexed Carboplatin or Gefitinib
  77. P2.01-051 Randomized Study of Pemetrexed Versus Erlotinib as Maintenance Therapy in Metastatic /Locally Advanced EGFR Mutation Negative NSCLC
  78. P3.01-076 QTWiST Analysis to Compare the Benefit of Gefitinib Versus Pemetrexed Platinum for Patients with EGFR Mutated NSCLC
  79. P1.03-021 A Prospective Observational Study to Evaluate Incidence of Thromboembolic Events during Platinum Based Chemotherapy in Lung Cancer
  80. P1.01-021 FISH and IHC Discordance in ALK Rearranged Non-Small Cell Lung Cancer
  81. P1.01-024 Plasma Circulating cfDNA as a Potential Biomarker in Clinical Management of NSCLC: Experience of Tata Memorial Hospital, India
  82. P1.01-023 ALK-Positive NSCLC: A TMH Experience
  83. PUB059 Gefitinib Versus Pemetrexed-Platinum Therapy in EGFR Activating Mutated Lung Cancer: Impact on Brain Metastasis
  84. 432PQTWiST analysis to compare the benefit of maintenance Erlotinib versus pemetrexed patients with EGFR non mutated NSCLC
  85. Practice Patterns and Outcomes for Pemetrexed Plus Platinum Doublet as Neoadjuvant Chemotherapy in Adenocarcinomas of Lung: Looking Beyond the Usual Paradigm
  86. Development and validation of a predictive score, for identifying poor eastern cooperative oncology group performance status (performance status 3–4) advanced nonsmall cell lung cancer patients who are likely to benefit from tyrosine kinase inhibitors
  87. Comparison of paclitaxel-cetuximab chemotherapy versus metronomic chemotherapy consisting of methotrexate and celecoxib as palliative chemotherapy in head and neck cancers
  88. Impact of exon 19 versus exon 21 EGFR-activating mutation on outcomes with upfront pemetrexed–carboplatin chemotherapy
  89. Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?
  90. Osimertinib in Indian patients with T790M-positive advanced nonsmall cell lung cancer
  91. 1294PReal world data of practice patterns and outcomes for pemetrexed plus platinum as neoadjuvant chemotherapy in adenocarcinomas of lung from a tertiary cancer center of India: Looking beyond the usual paradigm
  92. Bayesian relative survival : An illustration with lung cancer patients data
  93. A Study to Assess the Feasibility of Introducing Early Palliative Care in Ambulatory Patients with Advanced Lung Cancer
  94. Epidermal growth factor receptor exon 20 mutation in lung cancer: Types, incidence, clinical features and impact on treatment
  95. EGFR testing scenario across 111 centres in India: A questionnaire-based survey.
  96. Feasibility and outcome of repeat biopsy upon progression on tyrosine kinase inhibitors in patients with EGFR mutation positive adenocarcinoma of lung-an Indian tertiary cancer centre experience.
  97. Reference Data for Standardized Quality of Life Questionnaires in Indian Patients with Brain Metastases from Non-small Cell Lung Cancer: Results from a Prospective Study
  98. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
  99. ROS1 rearranged nonsmall cell lung cancer and crizotinib: An Indian experience
  100. Drug-sensitive FGFR3 mutations in lung adenocarcinoma
  101. EGFR mutation in squamous cell carcinoma of the lung: Does it carry the same connotation as in adenocarcinomas?
  102. P3.02b-007 Differential Efficacy of Gefitinib in Exon 19 or Exon 21 Mutated Adenocarcinoma Lung
  103. P3.02b-065 Third Line Therapy in EGFR Positive Advanced Non-Small Cell Lung Cancer
  104. P3.02b-090 Pemetrexed versus Gefitinib in EGFR Mutation Positive Lung Cancer: Results of a Phase 3 Study from India
  105. P3.02b-094 Rebiopsy Post Progression in EGFR Mutated Lung Cancer
  106. PUB118 Pre-Chemotherapy EGFR Mutation Status & Outcomes with Second Line Gefitinib in Advanced Adenocarcinoma Lung
  107. P3.02b-055 Impact of Pemetrexed Chemotherapy in Exon 19 or Exon 21 Mutated NSCLC
  108. P3.02b-058 Second-Line Therapy in EGFR Activating Mutation Positive Advanced NSCLC: Analysis from a Randomized Phase III First-Line Trial
  109. Feasibility of molecular testing in a multicenter study with geographical variation in India: Epidermal growth factor receptor mutation as a model molecular test
  110. Nivolumab instills hope in a hopeless situation in advanced nonsmall cell lung cancer with poor performance status
  111. Repeat biopsy in epidermal growth factor receptor mutation-positive nonsmall cell lung cancer: Feasibility, limitations, and clinical utility in Indian patients
  112. Ceritinib in anaplastic lymphoma kinase-positive nonsmall cell lung cancer among patients who were previously exposed to crizotinib: Experience from the Indian subcontinent
  113. Epidermal growth factor receptor positive lung cancer: The nontrial scenario
  114. Expanded panel test detecting mesenchymal-epithelial transition amplification leading to effective treatment in adenocarcinoma lung
  115. Chandrani et al. suppl Methods and Figures 20161110
  116. Chandrani et al. Supplementary Tables 20161110
  117. Aggressive Surgery in Palliative Setting of Lung Cancer: Is it Helpful?
  118. EGFR mutation in squamous cell carcinoma of lung – Does it carry the same connotation as in adenocarcinomas?
  119. ALK Positive Lung Cancer: Clinical Profile, Practice and Outcomes in a Developing Country
  120. Epidermal Growth Factor Receptor Mutational Status and Brain Metastases in Non-Small-Cell Lung Cancer
  121. Lung cancer in the Indian subcontinent
  122. Effect of EGFR mutations on outcomes in NSCLC with brain metastases.
  123. Curative intent therapy in oligometastatic lung cancer with an unresectable primary with N3 nodes: case report and review of the literature
  124. A cross-sectional observation study regarding patients and their physician willingness to wait for driver mutation report in nonsmall-cell lung cancer
  125. 175P ALK positive lung cancer: Clinical profile and outcomes in a developing country
  126. Weekly paclitaxel as metronomic palliative chemotherapy in small cell lung cancer
  127. Epidermal Growth Factor Receptor Mutation in Small Cell Lung Cancer Patients in an Indian Tertiary Care Oncology Hospital: Incidence and Clinical Outcome
  128. 3051 Relevance of performance status as a prognosticator in EGFR mutant NSCLC
  129. A cross sectional retrospective study regarding patients and their physician willingness to wait for driver mutation report in NSCLC.
  130. The importance of brain metastasis in EGFR mutation positive NSCLC patients
  131. Efficacy and safety of metronomic administration of paclitaxel for advanced recurrent non-small-cell lung cancer
  132. Induction Chemotherapy in Locally Advanced Pharyngolaryngeal Cancers with Stridor: Is It Feasible and Safe?
  133. Baby-step chemotherapy as a way to deliver chemotherapy in poor PS small cell lung cancer.
  134. Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer
  135. Phase III randomized trial comparing gefitinib to gefitinib with pemetrexed-carboplatin chemotherapy in patients with advanced untreated EGFR mutant non-small cell lung cancer (gef vs gef+C).
  136. Phase III Non-inferiority Study Evaluating Efficacy and Safety of Low Dose Gemcitabine Compared to Standard Dose Gemcitabine With Platinum in Advanced Squamous Lung Cancer
  137. 177PReal-world experience of ALK positive NSCLC from India
  138. 55ORadiogenomic signatures of NSCLC brain metastases: A potential non-invasive imaging marker for ALK mutation
  139. P1.01-88 PS 2 Patients with Advanced EGFR Mutant NSCLC: Subset Analysis of a Phase III Randomized Trial Comparing Gefitinib to Gefitinib with Chemotherapy
  140. P2.01-102 Outcome of Patients with EGFR Exon 19 Mutation in a Phase III Randomized Trial Comparing Gefitinib to Gefitinib with Chemotherapy
  141. Use of lorlatinib subsequent to crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: Indian experience
  142. Quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of a Phase III randomized trial to compare the benefit of gefitinib versus pemetrexed/ carboplatin for epidermal growth factor receptor-mutated non-small cell lung cancer
  143. Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: A single center retrospective analysis
  144. ROS1 mutation non-small cell lung cancer—access to optimal treatment and outcomes
  145. Epidermal growth factor receptor-mutated non-small-cell lung cancer: A primer on contemporary management
  146. Assessment of plasma derived microbiome profiles in lung cancer using targeted and whole exome sequencing
  147. Defining the role of pragmatic clinical trials in cancer clinical research: outcomes of a collaborative workshop hosted by the European Organisation for Research and Treatment of Cancer
  148. Safety and Efficacy of Alectinib in the First Line for ALK-Mutated Lung Cancer: A Real-World Data from India
  149. Safety and Efficacy of Alectinib in the First Line for ALK-Mutated Lung Cancer: A Real-World Data from India
  150. The impact of co-occurring tumor suppressor mutations with mEGFR as early indicators of relapse in lung cancer
  151. Clinical characteristics and first-line palliative treatment patterns in 3,414 patients with advanced lung cancer in India
  152. Pleuropulmonary Blastoma: Outcomes of Patients Treated with Curative Intent Protocols
  153. Unilateral Retinoblastoma: Audit of Outcomes of Children treated with Curative Treatment Protocol
  154. A Novel Deep Learning-Based (3D U-Net Model) Automated Pulmonary Nodule Detection Tool for CT Imaging
  155. Pregabalin for chronic cough due to lung cancer: randomized, double-blind, placebo-controlled trial
  156. Deep Diving Into the Fusion Across Cancer Types in the Indian Population From Formalin-Fixed Paraffin-Embedded RNA-Exome Data: A Road to Discovering Novel Rearrangements With Clinical Relevance
  1. 214P Study of treatment outcome in adults with TFE related RCC
  2. A competing risk analysis of death patterns in male genitourinary cancer
  3. P.14.50 Clinicopathological spectrum of intracranial germ cell tumors: an Indian tertiary cancer center experience
  4. Treatment outcomes of metastatic nonclear cell renal cell carcinoma: A single institution retrospective analysis
  5. Metastatic Renal Cell Cancer—Systemic Therapy
  6. Poor Risk Advanced Renal Cell Carcinoma: Outcomes from a Registry in a Tertiary Cancer Center
  7. Patterns of Care and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma-Results From a Tertiary Cancer Center in India
  8. Initial experience with first-line pazopanib in the treatment of metastatic renal cell carcinoma: A single institution data
  9. Patterns of care and outcomes for second-line targeted therapy in metastatic renal cell carcinomas: A registry based analysis
  10. Efficacy and safety of sorafenib in advanced renal cell cancer and validation of Heng criteria
  11. Epidemiology of male seminomatous and nonseminomatous germ cell tumors and response to first-line chemotherapy from a tertiary cancer center in India
  12. Epidemiology of male seminomatous (SGCT) and non-seminomatous germ cell tumours (NSGCT) and response to first line chemotherapy (CT) from a tertiary cancer centre in India.
  13. Palliative chemotherapy in carcinoma penis: Does platinum and taxane combination holds a promise?
  14. Sunitinib in metastatic renal cell carcimoma: A single-center experience
  15. Role of paclitaxel and platinum-based adjuvant chemotherapy in high-risk penile cancer
  1. Role of palliative chemotherapy and targeted therapy in advanced esophageal and gastroesophageal junction cancers
  2. Outcomes with Palliative Weekly Paclitaxel in Advanced, Recurrent, and Metastatic Esophageal Cancer – Real World Experience
  3. Potential role of metronomic chemotherapy in the treatment of esophageal and gastroesophageal cancer
  4. Efficacy and Safety of Induction Chemotherapy in Esophageal Cancer with Airway Involvement
  5. Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer: Retrospective Data Analysis from an Indian Centre
  6. Clinical Outcome in Definitive Concurrent Chemoradiation With Weekly Paclitaxel and Carboplatin for Locally Advanced Esophageal and Junctional Cancer
  7. Metronomics in low and middle income countries: India showing the way!
  1. Association of Immune-Related Adverse Effects and Survival in Solid Tumor Patients Treated with PD1 Inhibitors
  2. Demographics, Outcomes, Prognostic Factors in Adolescent-Adult Non-metastatic Ewing’s Sarcomas- Experience from a Tertiary Cancer Center in India
  3. Outcomes of Ewing sarcoma in adults over 40 years of age from a low-middle income country
  4. G8 and VES-13 as screening tools for geriatric assessment and predictors of survival in older Indian patients with cancer
  5. Vascular endothelial growth factor as a potential prognosticator in Ewing Sarcoma: a tertiary care cancer center experience from India
  6. Testing and interpreting assumptions of COX regression analysis
  7. Author Reply to: Sahoo, Batra et al. and Mullapally et al.
  8. Survey for geriatric assessment in practicing oncologists in India
  9. Concomitant use of corticosteroids and immune checkpoint inhibitors in patients with solid neoplasms: A real-world experience from a tertiary cancer center
  10. Impact of Molecular Tumor Board on the Clinical Management of Patients With Cancer
  11. Caregiver burden in older Indian patients with cancer- Experience from a tertiary care center
  12. Prevalence and outcomes of frailty in older patients with cancer: A prospective study from geriatric oncology clinic.
  13. Geriatric assessment as a predictor of survival among older Indian patients with cancer.
  14. Comprehensive Development and Implementation of Good Laboratory Practice for NGS Based Targeted Panel on Solid Tumor FFPE Tissues in Diagnostics
  15. Actionable Activating Oncogenic ERRB2/HER2 Transmembrane and Juxtamembrane Domain Mutations
  16. Effect of mastitis on lactation curves in purebred Jersey cows
  17. Patterns of epidermal growth factor receptor testing across 111 tertiary care centers in India: Result of a questionnaire-based survey
  18. An Algorithm to Define the Optimum Biological Dose of Metronomic Chemotherapy
  19. Immunotherapy in advanced cancers and predictor factors for outcome: An Indian experience.
  20. Diagnostic quandary over a cheek(y) neoplasm
  21. Supplementary Material
  22. Strategic approaches to overcome resistance against Gram negative pathogens using β-lactamase inhibitors and β-lactam enhancers: The activity of three novel diazabicyclooctanes, WCK 5153, zidebactam (WCK 5107), and WCK 4234
  23. “The clinical utility and safety of Short‐course Immune check point inhibitors ( ICI ) in multiple tumors ‐ A real world multicentric study from India”
  24. Deviation from standard cancer treatment during the first wave of the COVID-19 pandemic in India: A cross-sectional study
  25. Optical and structural characterization of high crystalline β-Ga2O3 films prepared using an RF magnetron sputtering
  26. Demographics, Pattern of Care, and Outcome Analysis of Malignant Melanomas – Experience From a Tertiary Cancer Centre in India
  27. 1705P The correlation of the ECOG performance status with vulnerabilities in the geriatric assessment: A retrospective cohort study
  28. ADME gene polymorphisms do not influence the pharmacokinetics of docetaxel: Results from a population pharmacokinetic study in Indian cancer patients
  29. Comparison of validated screening tools for the assessment of potentially inappropriate medications in older Indian patients with cancer.
  30. The use of G8 and VES13 as screening and prognostic tools in older Indian patients with cancer.
  31. Caregiver burden in older Indian patients with cancer: Experience from a tertiary care center.
  32. Accuracy of the CARG chemotherapy toxicity risk prediction tool in older Indian patients with cancer.
  33. Adolescent-adult nonmetastatic Ewing sarcoma-Experience from a large developing country
  34. Immune checkpoint inhibitors in patients with solid tumors and poor performance status: A prospective data from the real-world settings
  35. Impact of sex of the patient on efficacy and safety of cancer immunotherapy: A retrospective audit
  36. A real-world data of Immune checkpoint inhibitors in solid tumors from India
  37. Adolescent-Adult Non-metastatic Ewing Sarcoma- Experience from a large developing country
  38. Rare case of Skene gland adenocarcinoma with RET- rearrangement
  39. Polypharmacy and potentially inappropriate medication use in older Indian patients with cancer: A prospective observational study
  40. Algorithm to choose the appropriate test for comparison between two groups
  41. Authors’ reply to Patel, Gupta et al., and Jha et al.
  42. Authors’ reply to Divya et al
  43. Authors’ reply to Dhanushkodi et al. and Chalissery
  44. COVID-19 in cancer patients on active systemic therapy – Outcomes from LMIC scenario with an emphasis on need for active treatment
  45. Lymphopenia during chemoradiation—foe or friend
  46. Appendix I Quartz Paper CO submission Revised
  47. Assessing Metronomic Chemotherapy for Progressive Pediatric Solid Malignant Tumors
  48. Table S1
  49. Table S3
  50. Supplementary Figure 1
  51. Table S2
  52. Agreement analysis between three different short geriatric screening scales in patients undergoing chemotherapy for solid tumors
  53. 390PLiquid biopsies in clinical oncology: Review of validation results
  54. EMERALD: Emergency visit audit of patients treated under medical oncology in a tertiary cancer center: Logical steps to decrease the burden
  55. Phase III randomized trial comparing intravenous to oral iron in patients with cancer-related iron deficiency anemia not on erythropoiesis stimulating agents: Noronha et al.
  56. Adherence to and Implementation of ASCO Antiemetic Guidelines in Routine Practice in a Tertiary Cancer Center in India
  57. Supplementary Data
  58. Bayesian accelerated failure time and its application in Chemotherapy drug treatment trial
  59. Determining an Optimum Biological Dose of A Metronomic Chemotherapy
  60. Taxane Combination Chemotherapy in Breast Cancer: Experience from a Tertiary Cancer Centre in India
  61. Survey of Implementation of Antiemetic Prescription Standards in Indian Oncology Practices and Its Adherence to the American Society of Clinical Oncology Antiemetic Clinical Guideline
  62. biyoistatistik8-2-1
  63. Next generation metronomic chemotherapy—report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6–8 May 2016, Mumbai
  64. Clinico-pathological Study of Limb Salvage Surgery for Osteosarcoma: Experience in a Rural Cancer Center
  65. Weekly cisplatin (30–40 mg/m2) as radiosensitizer: Is it high or moderate emetic agent?
  66. Utility of driver mutation
  67. Phase III open label randomized controlled trial comparing intravenous iron sucrose to oral ferrous sulphate (without erythropoiesis stimulating agents) in the treatment of cancer related iron deficiency anemia.
  68. Survey of implementation of antiemetic prescription standards in Indian oncology practices and adherence to ASCO’s antiemetic clinical guideline.
  69. Tolerance of weekly metronomic paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin
  70. Outcomes of advanced epithelial ovarian cancer with integration of metronomic chemotherapy: An Indian rural cancer centre experience
  71. Development and validation of a questionnaire to measure preferences and expectations of patients undergoing palliative chemotherapy: EXPECT questionnaire
  72. Concordance of epidermal growth factor receptor mutation detection in bodily fluids other than blood with tissue biopsy: A retrospective analysis
  73. Efficacy and safety of low dose immunotherapy in palliative setting of advanced solid tumours
  74. 1049P Efficacy and safety of low dose immunotherapy in palliative setting of advanced solid tumours
  75. Tolerance of weekly paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin
  76. An audit of cytoreductive surgeries in ovarian cancer from a rural based cancer center
  77. Predictivity of human papillomavirus positivity in advanced oral cancer
  78. Association of immune-related adverse effects and survival in responders treated with immune checkpoint inhibitors.
  79. CancerResStatTreat3515-2728831 073448
  80. Concomitant use of antibiotics and immune checkpoint inhibitors in patients with solid neoplasms: retrospective data from real-world settings
  81. Abstract A28: Concomitant use of antibiotics and immune checkpoint inhibitors in patients with solid neoplasms: Retrospective data from real-world settings
  82. Extent of re-excision, sequence/timing of salvage re-irradiation, and disease-free interval impact upon clinical outcomes in recurrent/progressive ependymoma
  83. Authors’ reply to Kulkarni et al. and Wiwanitkit
  84. Retrospective audit of clinico-pathologic features and treatment outcomes in a cohort of elderly non-Hodgkin’s lymphoma patients in a tertiary cancer center
  85. Survey of the State of Implementation of the American Society of Clinical Oncology/Oncology Nursing Society Safety Standards for Chemotherapy Administration in India
  86. Burden and Outcomes of Pressure Ulcers in Cancer Patients Receiving the Kerala Model of Home Based Palliative Care in India: Results From a Prospective Observational Study
  87. Dessai et al-2014-Psycho-Oncology
  88. Pelvic Exenteration: Experience from a Rural CancerCenter in Developing World
  89. Authors’ reply to Krishnamurthy, Bhosale et al., and Mohan et al.
  90. Authors’ reply to Dubey et al. and Bhattacharyya et al.
  91. Authors’ reply to Jiwnani et al.
  92. Metronomics: The next generation of multitargeted therapy
  93. An audit of febrile neutropenia cases from a rural cancer center in India
  94. Pattern of infection, therapy, outcome and risk stratification of patients with febrile neutropenia in a tertiary care oncology hospital in India
  95. Magnitude and Implications of Interfraction Variations in Organ Doses during High Dose Rate Brachytherapy of Cervix Cancer: A CT Based Planning Study
  96. Predicting complications of chemotherapy-induced febrile neutropenia: A single-center experience.
  97. Metronomic therapy: Chemotherapy revisited
  98. Patterns of care in geriatric cancer patients – An audit from a rural based hospital cancer registry in Kerala
  99. Pilot study of single-day distress screening with the NCCN distress thermometer to evaluate the feasibility of routine distress screening in tertiary cancer center in rural India
  100. How well do Elderly patients with cervical cancer tolerate definitive radiochemotherapy using RapidArc? Results from an institutional audit comparing elderly versus younger patients
  101. Exploring the role of systemic therapy in adult adrenocortical carcinoma: A single-center experience
  102. Leptomeningeal metastasis from extracranial solid tumors
  103. Authors’ reply to Vora et al. and Singh et al.
  104. Initial experience of a geriatric oncology clinic in a tertiary cancer center in India
  105. Authors’ reply to Daddi
  106. Skin rash: Disease or drug?
  107. Authors’ reply to Chandrasekharan et al. and Abbas
  108. Cytomegalovirus infection in solid malignancies
  109. Authors’ reply to Kumar et al. and Kannan et al.
  110. Cancer thrombosis: Narrative review
  111. Authors’ reply to Kies and Katna et al.
  112. Authors’ response to Vora and Rajpurohit
  113. Authors’ reply to Batra et al., Chadha et al., and Deb et al.
  114. Author’s reply to Tripathi et al. and Memon et al.
  115. THE COMPREHENSIVE GERIATRIC PROFILE OF INDIAN ONCOLOGY PATIENTS: EXPERIENCE OF A GERIATRIC ONCOLOGY CLINIC IN A TERTIARY CANCER CENTER IN INDIA
  116. DPYD Mutation in Indian Patients
  117. Author Reply to Kapoor et al.
  118. Effect of parity on the shape of lactation curves in purebred Jersey cows in Indian conditions
  119. Effect of growth variables on properties of gallium oxide thin films grown by sputtering
  120. Effects of post-growth annealing in vacuum and Zn vapor on the electrical and optical properties of magnetron sputtered GaMgZnO films
  121. Antiemetic prophylaxis with temozolomide: an audit from a tertiary care center
  122. Single Agent Weekly Paclitaxel as Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer: A Feasibility Study
  123. Can point doses predict volumetric dose to rectum and bladder: A CT-based planning study in high dose rate intracavitary brachytherapy of cervical carcinoma?
  124. Dosimetric risk estimates of radiation-induced malignancies after intensity modulated radiotherapy
  125. Supplementary Material 1
  126. Supplementary Material 2
  127. Appendix 5
  128. Chiral Separation and Thermodynamic Investigation of WCK 3023: A Novel Oxazolidinone Antibacterial Agent, Application to Pre‐clinical Pharmacokinetic Study
  129. Author response to: Reducing dexamethasone premedication with paclitaxel
  130. Low doses in immunotherapy: Are they effective?
  1. Comprehensive Genomic Profiling of Anaplastic Thyroid Cancer Identifies Alterations in THRA, a Potential Modifier of Cellular Plasticity
  2. Assessment of plasma derived microbiome profiles in lung cancer using targeted and whole exome sequencing
  3. Genomic Characterization of Papillary Thyroid Cancer Reveals Germline Mutations Associated With Congenital Hypothyroidism
  4. Triple Oral Metronomic Chemotherapy Versus Chemotherapy of Physician Discretion After Failure of Platinum-Based Therapy in Advanced Head and Neck Cancer: A Phase III Randomized Study (METRO-CHASE Study)
  5. Evaluating the prognostic value of tumor-derived circulating endothelial cells and their progenitors in platinum-refractory oral cancer patients for response to triple metronomic therapy
  6. Defining the role of pragmatic clinical trials in cancer clinical research: outcomes of a collaborative workshop hosted by the European Organisation for Research and Treatment of Cancer
  7. Outcomes of selective neck dissection in node positive oral cavity squamous cell carcinoma
  8. PD-L1 in Oral Cavity Cancers—Audit for Tertiary Care Center in India
  9. Safety and Efficacy of Alectinib in the First Line for ALK-Mutated Lung Cancer: A Real-World Data from India
  10. Safety and Efficacy of Alectinib in the First Line for ALK-Mutated Lung Cancer: A Real-World Data from India
  11. Phase 3 randomized study of physician choice vs metronomic chemotherapy in platinum refractory/ineligible head and neck cancer in palliative setting with survival outcomes
  12. Phase 3 randomized study of physician choice vs metronomic chemotherapy in platinum refractory/ineligible head and neck cancer in palliative setting with survival outcomes
  13. The impact of co-occurring tumor suppressor mutations with mEGFR as early indicators of relapse in lung cancer
  14. Clinical characteristics and first-line palliative treatment patterns in 3,414 patients with advanced lung cancer in India
  15. Pleuropulmonary Blastoma: Outcomes of Patients Treated with Curative Intent Protocols
  16. Unilateral Retinoblastoma: Audit of Outcomes of Children treated with Curative Treatment Protocol
  17. Ewing’s Sarcoma of the Head and Neck: Outcomes of 101 Patients Treated at a Tertiary Cancer Center
  18. Compartmentalization of High Infratemporal Fossa in Oral Cavity Squamous Cell Carcinomas and Its Impact on Clinical Outcome
  19. A Novel Deep Learning-Based (3D U-Net Model) Automated Pulmonary Nodule Detection Tool for CT Imaging
  20. Pregabalin for chronic cough due to lung cancer: randomized, double-blind, placebo-controlled trial
  21. Nose and sinuses
  22. Deep Diving Into the Fusion Across Cancer Types in the Indian Population From Formalin-Fixed Paraffin-Embedded RNA-Exome Data: A Road to Discovering Novel Rearrangements With Clinical Relevance
  23. Indian clinical practice consensus guidelines for the management of nasopharyngeal cancer
  24. Indian clinical practice consensus guidelines for the management of locoregional hypopharyngeal cancer – Update 2023

“Let science serve people, not the other way around.”

To consult with Dr. (Prof.) Vijay Patil or explore SunAct’s advanced oncology programs, visit sunactcancer.com/contact.

proceed to call

Share your details below, and we’ll reach out to you without delay.

Disclaimer : We will be using this information for calling purposes only.

SunAct genitourinary cancer case study on GPC3-targeted CAR T therapy for refractory non-seminomatous germ cell tumor
SunAct genitourinary cancer case study on GPC3-targeted CAR T therapy for refractory non-seminomatous germ cell tumor
SunAct colon cancer case study highlighting TCR-based approach in metastatic colon cancer with lung lesions
SunAct colon cancer case study highlighting TCR-based approach in metastatic colon cancer with lung lesions
SunAct breast cancer case study showcasing HER2-positive treatment with CAR T-cell therapy
SunAct breast cancer case study showcasing HER2-positive treatment with CAR T-cell therapy
SunAct head and neck cancer case study using TCR-p53 therapy in inoperable squamous cell carcinoma
SunAct case study featuring gamma delta T-cell therapy for recurrent tongue carcinoma with extensive metastasis
SunAct case study featuring gamma delta T-cell therapy for recurrent tongue carcinoma with extensive metastasis
SunAct head and neck cancer case study on salivary ductal carcinoma managed with advanced therapies
SunAct head and neck cancer case study on salivary ductal carcinoma managed with advanced therapies
SunAct case study on GD2-targeted CAR T therapy for diffuse midline glioma in a 22-year-old male
SunAct case study on GD2-targeted CAR T therapy for diffuse midline glioma in a 22-year-old male
SunAct CNS case study on GBM treatment using multiple gene mutation targeting in a 36-year-old male
SunAct CNS case study on GBM treatment using multiple gene mutation targeting in a 36-year-old male